Countering the problem of falsified and substandard drugs:
Gespeichert in:
| Körperschaft: | |
|---|---|
| Weitere Verfasser: | |
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Washington, D.C.
National Academies Press
[2013]
|
| Schlagworte: | |
| Online-Zugang: | FAW01 FAW02 Volltext |
| Beschreibung: | Online resource; title from resource home page (National Academies Press, viewed June 12, 2013) |
| Beschreibung: | 1 online resource (xxiv, 351 pages) illustrations (chiefly color), color maps |
| ISBN: | 0309269393 0309269407 9780309269391 9780309269407 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV043027550 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 151120s2013 |||| o||u| ||||||eng d | ||
| 020 | |a 0309269393 |9 0-309-26939-3 | ||
| 020 | |a 0309269407 |9 0-309-26940-7 | ||
| 020 | |a 9780309269391 |9 978-0-309-26939-1 | ||
| 020 | |a 9780309269407 |9 978-0-309-26940-7 | ||
| 035 | |a (OCoLC)839275199 | ||
| 035 | |a (DE-599)BVBBV043027550 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-1046 |a DE-1047 | ||
| 082 | 0 | |a 338.4/76151 |2 23 | |
| 110 | 2 | |a Institute of Medicine (U.S.) |b Committee on Understanding the Global Public Health Implications of Substandard, Falsified, and Counterfeit Medical Products |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Countering the problem of falsified and substandard drugs |c Committee on Understanding the Global Public Health Implications of Substandard, Falsified, and Counterfeit Medical Products, Board on Global Health ; Gillian J. Buckley and Lawrence O. Gostin, editors ; Institute of Medicine of the National Academies |
| 264 | 1 | |a Washington, D.C. |b National Academies Press |c [2013] | |
| 264 | 4 | |c © 2013 | |
| 300 | |a 1 online resource (xxiv, 351 pages) |b illustrations (chiefly color), color maps | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Online resource; title from resource home page (National Academies Press, viewed June 12, 2013) | ||
| 505 | 8 | |a Introduction -- The effects of falsified and substandard drugs -- The magnitude of the problem -- Causes of falsified and substandard drugs -- Weaknesses in the drug distribution chain -- Detection technology -- An international code of practice for falsified and substandard medicines | |
| 505 | 8 | |a "The adulteration and fraudulent manufacture of medicines is an old problem, vastly aggravated by modern manufacturing and trade. In the last decade, impotent antimicrobial drugs have compromised the treatment of many deadly diseases in poor countries. More recently, negligent production at a Massachusetts compounding pharmacy sickened hundreds of Americans. While the national drugs regulatory authority (hereafter, the regulatory authority) is responsible for the safety of a country's drug supply, no single country can entirely guarantee this today. The once common use of the term counterfeit to describe any drug that is not what it claims to be is at the heart of the argument. In a narrow, legal sense a counterfeit drug is one that infringes on a registered trademark. The lay meaning is much broader, including any drug made with intentional deceit. Some generic drug companies and civil society groups object to calling bad medicines counterfeit, seeing it as the deliberate conflation of public health and intellectual property concerns. Countering the Problem of Falsified and Substandard Drugs accepts the narrow meaning of counterfeit, and, because the nuances of trademark infringement must be dealt with by courts, case by case, the report does not discuss the problem of counterfeit medicines"--Publisher's description | |
| 650 | 4 | |a Counterfeit Drugs | |
| 650 | 4 | |a Fraud / prevention & control | |
| 650 | 4 | |a Drug Contamination / prevention & control | |
| 650 | 4 | |a Pharmaceutical Preparations / standards | |
| 650 | 4 | |a Quality Control | |
| 650 | 4 | |a International Cooperation | |
| 650 | 7 | |a BUSINESS & ECONOMICS / Industries / General |2 bisacsh | |
| 650 | 7 | |a Fraud / Prevention |2 fast | |
| 650 | 7 | |a Pharmaceutical industry |2 fast | |
| 650 | 7 | |a Pharmaceutical industry / Quality control |2 fast | |
| 650 | 4 | |a Industrie | |
| 650 | 4 | |a Wirtschaft | |
| 650 | 4 | |a Pharmaceutical industry | |
| 650 | 4 | |a Pharmaceutical industry |x Quality control | |
| 650 | 4 | |a Fraud |x Prevention | |
| 700 | 1 | |a Buckley, Gillian J. |4 edt | |
| 700 | 1 | |a Gostin, Lawrence O. |e Sonstige |4 oth | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |a Institute of Medicine (U.S.). Committee on Understanding the Global Public Health Implications of Substandard, Falsified, and Counterfeit Medical Products |t Countering the problem of falsified and substandard drugs |
| 856 | 4 | 0 | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=867887 |x Aggregator |3 Volltext |
| 912 | |a ZDB-4-EBA | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-028452204 | ||
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=867887 |l FAW01 |p ZDB-4-EBA |q FAW_PDA_EBA |x Aggregator |3 Volltext | |
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=867887 |l FAW02 |p ZDB-4-EBA |q FAW_PDA_EBA |x Aggregator |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804175381699231744 |
|---|---|
| any_adam_object | |
| author2 | Buckley, Gillian J. |
| author2_role | edt |
| author2_variant | g j b gj gjb |
| author_corporate | Institute of Medicine (U.S.) Committee on Understanding the Global Public Health Implications of Substandard, Falsified, and Counterfeit Medical Products |
| author_corporate_role | aut |
| author_facet | Buckley, Gillian J. Institute of Medicine (U.S.) Committee on Understanding the Global Public Health Implications of Substandard, Falsified, and Counterfeit Medical Products |
| author_sort | Institute of Medicine (U.S.) Committee on Understanding the Global Public Health Implications of Substandard, Falsified, and Counterfeit Medical Products |
| building | Verbundindex |
| bvnumber | BV043027550 |
| collection | ZDB-4-EBA |
| contents | Introduction -- The effects of falsified and substandard drugs -- The magnitude of the problem -- Causes of falsified and substandard drugs -- Weaknesses in the drug distribution chain -- Detection technology -- An international code of practice for falsified and substandard medicines "The adulteration and fraudulent manufacture of medicines is an old problem, vastly aggravated by modern manufacturing and trade. In the last decade, impotent antimicrobial drugs have compromised the treatment of many deadly diseases in poor countries. More recently, negligent production at a Massachusetts compounding pharmacy sickened hundreds of Americans. While the national drugs regulatory authority (hereafter, the regulatory authority) is responsible for the safety of a country's drug supply, no single country can entirely guarantee this today. The once common use of the term counterfeit to describe any drug that is not what it claims to be is at the heart of the argument. In a narrow, legal sense a counterfeit drug is one that infringes on a registered trademark. The lay meaning is much broader, including any drug made with intentional deceit. Some generic drug companies and civil society groups object to calling bad medicines counterfeit, seeing it as the deliberate conflation of public health and intellectual property concerns. Countering the Problem of Falsified and Substandard Drugs accepts the narrow meaning of counterfeit, and, because the nuances of trademark infringement must be dealt with by courts, case by case, the report does not discuss the problem of counterfeit medicines"--Publisher's description |
| ctrlnum | (OCoLC)839275199 (DE-599)BVBBV043027550 |
| dewey-full | 338.4/76151 |
| dewey-hundreds | 300 - Social sciences |
| dewey-ones | 338 - Production |
| dewey-raw | 338.4/76151 |
| dewey-search | 338.4/76151 |
| dewey-sort | 3338.4 576151 |
| dewey-tens | 330 - Economics |
| discipline | Wirtschaftswissenschaften |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04663nmm a2200613zc 4500</leader><controlfield tag="001">BV043027550</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">151120s2013 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0309269393</subfield><subfield code="9">0-309-26939-3</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0309269407</subfield><subfield code="9">0-309-26940-7</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780309269391</subfield><subfield code="9">978-0-309-26939-1</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780309269407</subfield><subfield code="9">978-0-309-26940-7</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)839275199</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV043027550</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-1046</subfield><subfield code="a">DE-1047</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">338.4/76151</subfield><subfield code="2">23</subfield></datafield><datafield tag="110" ind1="2" ind2=" "><subfield code="a">Institute of Medicine (U.S.)</subfield><subfield code="b">Committee on Understanding the Global Public Health Implications of Substandard, Falsified, and Counterfeit Medical Products</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Countering the problem of falsified and substandard drugs</subfield><subfield code="c">Committee on Understanding the Global Public Health Implications of Substandard, Falsified, and Counterfeit Medical Products, Board on Global Health ; Gillian J. Buckley and Lawrence O. Gostin, editors ; Institute of Medicine of the National Academies</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Washington, D.C.</subfield><subfield code="b">National Academies Press</subfield><subfield code="c">[2013]</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">© 2013</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (xxiv, 351 pages)</subfield><subfield code="b">illustrations (chiefly color), color maps</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Online resource; title from resource home page (National Academies Press, viewed June 12, 2013)</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Introduction -- The effects of falsified and substandard drugs -- The magnitude of the problem -- Causes of falsified and substandard drugs -- Weaknesses in the drug distribution chain -- Detection technology -- An international code of practice for falsified and substandard medicines</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">"The adulteration and fraudulent manufacture of medicines is an old problem, vastly aggravated by modern manufacturing and trade. In the last decade, impotent antimicrobial drugs have compromised the treatment of many deadly diseases in poor countries. More recently, negligent production at a Massachusetts compounding pharmacy sickened hundreds of Americans. While the national drugs regulatory authority (hereafter, the regulatory authority) is responsible for the safety of a country's drug supply, no single country can entirely guarantee this today. The once common use of the term counterfeit to describe any drug that is not what it claims to be is at the heart of the argument. In a narrow, legal sense a counterfeit drug is one that infringes on a registered trademark. The lay meaning is much broader, including any drug made with intentional deceit. Some generic drug companies and civil society groups object to calling bad medicines counterfeit, seeing it as the deliberate conflation of public health and intellectual property concerns. Countering the Problem of Falsified and Substandard Drugs accepts the narrow meaning of counterfeit, and, because the nuances of trademark infringement must be dealt with by courts, case by case, the report does not discuss the problem of counterfeit medicines"--Publisher's description</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Counterfeit Drugs</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Fraud / prevention & control</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Contamination / prevention & control</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical Preparations / standards</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Quality Control</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">International Cooperation</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">BUSINESS & ECONOMICS / Industries / General</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Fraud / Prevention</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmaceutical industry</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmaceutical industry / Quality control</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Industrie</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Wirtschaft</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical industry</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical industry</subfield><subfield code="x">Quality control</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Fraud</subfield><subfield code="x">Prevention</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Buckley, Gillian J.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gostin, Lawrence O.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="a">Institute of Medicine (U.S.). Committee on Understanding the Global Public Health Implications of Substandard, Falsified, and Counterfeit Medical Products</subfield><subfield code="t">Countering the problem of falsified and substandard drugs</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=867887</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-028452204</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=867887</subfield><subfield code="l">FAW01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=867887</subfield><subfield code="l">FAW02</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV043027550 |
| illustrated | Illustrated |
| indexdate | 2024-07-10T07:15:23Z |
| institution | BVB |
| isbn | 0309269393 0309269407 9780309269391 9780309269407 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-028452204 |
| oclc_num | 839275199 |
| open_access_boolean | |
| owner | DE-1046 DE-1047 |
| owner_facet | DE-1046 DE-1047 |
| physical | 1 online resource (xxiv, 351 pages) illustrations (chiefly color), color maps |
| psigel | ZDB-4-EBA ZDB-4-EBA FAW_PDA_EBA |
| publishDate | 2013 |
| publishDateSearch | 2013 |
| publishDateSort | 2013 |
| publisher | National Academies Press |
| record_format | marc |
| spelling | Institute of Medicine (U.S.) Committee on Understanding the Global Public Health Implications of Substandard, Falsified, and Counterfeit Medical Products Verfasser aut Countering the problem of falsified and substandard drugs Committee on Understanding the Global Public Health Implications of Substandard, Falsified, and Counterfeit Medical Products, Board on Global Health ; Gillian J. Buckley and Lawrence O. Gostin, editors ; Institute of Medicine of the National Academies Washington, D.C. National Academies Press [2013] © 2013 1 online resource (xxiv, 351 pages) illustrations (chiefly color), color maps txt rdacontent c rdamedia cr rdacarrier Online resource; title from resource home page (National Academies Press, viewed June 12, 2013) Introduction -- The effects of falsified and substandard drugs -- The magnitude of the problem -- Causes of falsified and substandard drugs -- Weaknesses in the drug distribution chain -- Detection technology -- An international code of practice for falsified and substandard medicines "The adulteration and fraudulent manufacture of medicines is an old problem, vastly aggravated by modern manufacturing and trade. In the last decade, impotent antimicrobial drugs have compromised the treatment of many deadly diseases in poor countries. More recently, negligent production at a Massachusetts compounding pharmacy sickened hundreds of Americans. While the national drugs regulatory authority (hereafter, the regulatory authority) is responsible for the safety of a country's drug supply, no single country can entirely guarantee this today. The once common use of the term counterfeit to describe any drug that is not what it claims to be is at the heart of the argument. In a narrow, legal sense a counterfeit drug is one that infringes on a registered trademark. The lay meaning is much broader, including any drug made with intentional deceit. Some generic drug companies and civil society groups object to calling bad medicines counterfeit, seeing it as the deliberate conflation of public health and intellectual property concerns. Countering the Problem of Falsified and Substandard Drugs accepts the narrow meaning of counterfeit, and, because the nuances of trademark infringement must be dealt with by courts, case by case, the report does not discuss the problem of counterfeit medicines"--Publisher's description Counterfeit Drugs Fraud / prevention & control Drug Contamination / prevention & control Pharmaceutical Preparations / standards Quality Control International Cooperation BUSINESS & ECONOMICS / Industries / General bisacsh Fraud / Prevention fast Pharmaceutical industry fast Pharmaceutical industry / Quality control fast Industrie Wirtschaft Pharmaceutical industry Pharmaceutical industry Quality control Fraud Prevention Buckley, Gillian J. edt Gostin, Lawrence O. Sonstige oth Erscheint auch als Druck-Ausgabe Institute of Medicine (U.S.). Committee on Understanding the Global Public Health Implications of Substandard, Falsified, and Counterfeit Medical Products Countering the problem of falsified and substandard drugs http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=867887 Aggregator Volltext |
| spellingShingle | Countering the problem of falsified and substandard drugs Introduction -- The effects of falsified and substandard drugs -- The magnitude of the problem -- Causes of falsified and substandard drugs -- Weaknesses in the drug distribution chain -- Detection technology -- An international code of practice for falsified and substandard medicines "The adulteration and fraudulent manufacture of medicines is an old problem, vastly aggravated by modern manufacturing and trade. In the last decade, impotent antimicrobial drugs have compromised the treatment of many deadly diseases in poor countries. More recently, negligent production at a Massachusetts compounding pharmacy sickened hundreds of Americans. While the national drugs regulatory authority (hereafter, the regulatory authority) is responsible for the safety of a country's drug supply, no single country can entirely guarantee this today. The once common use of the term counterfeit to describe any drug that is not what it claims to be is at the heart of the argument. In a narrow, legal sense a counterfeit drug is one that infringes on a registered trademark. The lay meaning is much broader, including any drug made with intentional deceit. Some generic drug companies and civil society groups object to calling bad medicines counterfeit, seeing it as the deliberate conflation of public health and intellectual property concerns. Countering the Problem of Falsified and Substandard Drugs accepts the narrow meaning of counterfeit, and, because the nuances of trademark infringement must be dealt with by courts, case by case, the report does not discuss the problem of counterfeit medicines"--Publisher's description Counterfeit Drugs Fraud / prevention & control Drug Contamination / prevention & control Pharmaceutical Preparations / standards Quality Control International Cooperation BUSINESS & ECONOMICS / Industries / General bisacsh Fraud / Prevention fast Pharmaceutical industry fast Pharmaceutical industry / Quality control fast Industrie Wirtschaft Pharmaceutical industry Pharmaceutical industry Quality control Fraud Prevention |
| title | Countering the problem of falsified and substandard drugs |
| title_auth | Countering the problem of falsified and substandard drugs |
| title_exact_search | Countering the problem of falsified and substandard drugs |
| title_full | Countering the problem of falsified and substandard drugs Committee on Understanding the Global Public Health Implications of Substandard, Falsified, and Counterfeit Medical Products, Board on Global Health ; Gillian J. Buckley and Lawrence O. Gostin, editors ; Institute of Medicine of the National Academies |
| title_fullStr | Countering the problem of falsified and substandard drugs Committee on Understanding the Global Public Health Implications of Substandard, Falsified, and Counterfeit Medical Products, Board on Global Health ; Gillian J. Buckley and Lawrence O. Gostin, editors ; Institute of Medicine of the National Academies |
| title_full_unstemmed | Countering the problem of falsified and substandard drugs Committee on Understanding the Global Public Health Implications of Substandard, Falsified, and Counterfeit Medical Products, Board on Global Health ; Gillian J. Buckley and Lawrence O. Gostin, editors ; Institute of Medicine of the National Academies |
| title_short | Countering the problem of falsified and substandard drugs |
| title_sort | countering the problem of falsified and substandard drugs |
| topic | Counterfeit Drugs Fraud / prevention & control Drug Contamination / prevention & control Pharmaceutical Preparations / standards Quality Control International Cooperation BUSINESS & ECONOMICS / Industries / General bisacsh Fraud / Prevention fast Pharmaceutical industry fast Pharmaceutical industry / Quality control fast Industrie Wirtschaft Pharmaceutical industry Pharmaceutical industry Quality control Fraud Prevention |
| topic_facet | Counterfeit Drugs Fraud / prevention & control Drug Contamination / prevention & control Pharmaceutical Preparations / standards Quality Control International Cooperation BUSINESS & ECONOMICS / Industries / General Fraud / Prevention Pharmaceutical industry Pharmaceutical industry / Quality control Industrie Wirtschaft Pharmaceutical industry Quality control Fraud Prevention |
| url | http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=867887 |
| work_keys_str_mv | AT instituteofmedicineuscommitteeonunderstandingtheglobalpublichealthimplicationsofsubstandardfalsifiedandcounterfeitmedicalproducts counteringtheproblemoffalsifiedandsubstandarddrugs AT buckleygillianj counteringtheproblemoffalsifiedandsubstandarddrugs AT gostinlawrenceo counteringtheproblemoffalsifiedandsubstandarddrugs |